Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | ACR | P10323 | 1/20 | 0.38 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11569510 | 0.81 | ALOX15 (0.47) | ATMTDP1L3MBTL1ALOX15HPGD | |
| Diphenyl Ethanedioat SCHEMBL2254079 | 0.81 | PARP10 (0.46) | PRSS1PRSS2PRSS3PARP10MEN1 | |
| SCHEMBL8069670 | 0.78 | MAPT (0.46) | ATMTDP1L3MBTL1HSD17B10 | |
| SCHEMBL4065601 | 0.77 | TDP1 (0.42) | PRSS1PRSS2PRSS3PARP10SMN1; SMN2 | |
| Water SCHEMBL27685948 | 0.76 | TDP1 (0.41) | PRSS1PRSS2PRSS3PARP10SMN1; SMN2 | |
| SCHEMBL58882 | 0.75 | TDP1 (0.44) | MEN1KMT2AATMTDP1L3MBTL1 | |
| SCHEMBL4869116 | 0.74 | PARP10 (0.47) | PRSS1PRSS2PRSS3PARP10MEN1 | |
| Diphenyl Ethanedioat SCHEMBL43364 | 0.73 | TDP1 (0.54) | ATMTDP1L3MBTL1ALOX15HPGD | |
| SCHEMBL237447 | 0.73 | CES2 (0.50) | SMN1; SMN2ATMTDP1L3MBTL1ALOX15 | |
| SCHEMBL11033789 | 0.73 | TDP1 (0.42) | ATMTDP1L3MBTL1ALOX15HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1236712-B1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | AJINOMOTO KK (JP) | 2008-08-06 | — | — | EP | claimed |
| US-6710056-B2 | PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. | AJINOMOTO CO., INC. (JP) | 2004-03-23 | — | — | US | claimed |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | AJINOMOTO CO. INC (JP) | 2003-06-12 | — | — | US | claimed |
| EP-1236712-A1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | claimed |
| EP-1226830-A2 | Combination therapy involving a sodium-hydrogen exchanger type 1 or NHE-1 inhibitor for use in treatment of ischemia | Pfizer Products Inc. (US) | 2002-07-31 | — | — | EP | claimed |
| US-20020099075-A1 | COMBINATION THERAPY | TRACEY WAYNE R (US) | 2002-07-25 | — | — | US | claimed |
| US-6423705-B1 | FOR ISCHEMIA BY ADMINISTERING AN NHE-1 INHIBITOR AND A SECOND COMPOUND SELECTED FROM COMPLEMENT MODULATOR, METABOLIC MODULATOR, ANTIAPOPTOTIC AGENT, NITRIC OXIDE SYNTHASE-RELATED AGENT, AND AN ENZYME/PROTEIN MODULATOR | PFIZER INC. | 2002-07-23 | — | — | US | claimed |
| US-20090194124-A1 | Hair Shaping Kit and Process Comprising at Least One Non-Hydroxide Imine | MALLE GERARD | 2009-08-06 | — | — | US | disclosed |
| US-20090139537-A1 | HAIR RELAXING COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE IMINE | L'OREAL S.A. | 2009-06-04 | — | — | US | disclosed |
| EP-1236712-B1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | AJINOMOTO KK (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1236712-B1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | AJINOMOTO KK (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | L'OREAL S.A. (FR) | 2005-06-23 | — | — | US | disclosed |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | L'OREAL | 2005-06-16 | — | — | US | disclosed |
| US-6423705-B1 | FOR ISCHEMIA BY ADMINISTERING AN NHE-1 INHIBITOR AND A SECOND COMPOUND SELECTED FROM COMPLEMENT MODULATOR, METABOLIC MODULATOR, ANTIAPOPTOTIC AGENT, NITRIC OXIDE SYNTHASE-RELATED AGENT, AND AN ENZYME/PROTEIN MODULATOR | PFIZER INC. | 2002-07-23 | — | — | US | disclosed |
| WO-2001042199-A1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | AJINOMOTO CO.,INC. (JP) | 2001-06-14 | — | — | WO | disclosed |
| US-5278189-A | Antilipemic agents | MATTHIAS RATH HOLDING B.V. (NL) | 1994-01-11 | — | — | US | disclosed |
| US-5230996-A | Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation | THERAPY 2000 (US) | 1993-07-27 | — | — | US | disclosed |
| EP-0532706-A4 | REDUCTION OF CARDIOVASCULAR VESSEL OCCLUSIONS WITH ASCORBATE AND LIPOPROTEIN (A) BINDING INHIBITORS | — | 1993-06-30 | — | — | EP | disclosed |
| EP-0532706-A1 | REDUCTION OF CARDIOVASCULAR VESSEL OCCLUSIONS WITH ASCORBATE AND LIPOPROTEIN (a) BINDING INHIBITORS. | THERAPY 2000 (US) | 1993-03-24 | — | — | EP | disclosed |
| WO-1991019488-A1 | REDUCTION OF CARDIOVASCULAR VESSEL OCCLUSIONS WITH ASCORBATE AND LIPOPROTEIN (a) BINDING INHIBITORS | THERAPY 2000 (US) | 1991-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | HABP2, F2, F7 | PRSS1 81/4885PRSS2 145/4885PRSS3 273/4885 |
| US-20090139537-A1 | HAIR RELAXING COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE IMINE | KRT18, INMT, INHA | PRSS1 3478/4885PRSS2 3242/4885PRSS3 2207/4885 |
| US-20090194124-A1 | Hair Shaping Kit and Process Comprising at Least One Non-Hydroxide Imine | KRT18, KIT, PRDM7 | PRSS1 4314/4885PRSS2 3742/4885PRSS3 3079/4885 |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | KRT18, INHA, H1-5 | PRSS1 4545/4885PRSS2 4251/4885PRSS3 3269/4885 |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | BHMT, KRT18, INMT | PRSS1 2914/4885PRSS2 2903/4885PRSS3 2582/4885 |
| US-20020099075-A1 | COMBINATION THERAPY | TFPI, SLC9A1, TFPI2 | PRSS1 28/4885PRSS2 339/4885PRSS3 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.